MicroRNAs in the pathobiology of multiple myeloma

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 823-837

  Lionetti, Marta ^a,b   Agnelli, Luca ^a   Lombardi, Luigia ^a   Tassone, Pierfrancesco ^c   Neri, Antonino ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Matarelli's Foundation   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Chromosomal abnormalities; Gene expression profiling; MicroRNAs; Multiple myeloma; Prognostic stratification

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ARGONAUTE 2 PROTEIN; BIM PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOTOXIC AGENT; DICER; DICER 1 PROTEIN; EXPORTIN 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 6; JANUS KINASE; LIGASE INHIBITOR; MDM2 PROTEIN INHIBITOR; MICRORNA; MICRORNA 150; MICRORNA 155; MICRORNA 17; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SMALL UNTRANSLATED RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BINDING SITE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CYTOGENETICS; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENE TARGETING; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR GENETICS; MULTIPLE MYELOMA; MYELOMA CELL; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOGENESIS; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; B-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MULTIPLE MYELOMA;

EID: 84866415670     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429274     Document Type: Review

References (137)

1. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 2004, 351, 1860-1873.
2. Rajkumar, S. V.; Kyle, R. A. Multiple myeloma: diagnosis and treatment. Mayo Clin. Proc. 2005, 80, 1371-1382.
3. Kyle, R. A.; Therneau, T. M.; Rajkumar, S. V.; Larson, D. R.; Plevak, M. F.; Melton, L. J. III. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer 2004, 101, 2667-2674.
4. Mitsiades, C. S.; Mitsiades, N.; Munshi, N. C.; Anderson, K. C. Focus on multiple myeloma. Cancer Cell 2004, 6, 439-444.
5. Kyle, R. A.; Rajkumar, S. V. Monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2006, 134, 573-589.
6. Kyle, R. A.; Therneau, T. M.; Rajkumar, S. V.; Offord, J. R.; Larson, D. R.; Plevak, M. F.; Melton, L. J. III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2002, 346, 564-569.
7. Rajkumar, S. V. Multiple myeloma. Curr. Probl. Cancer 2009, 33, 7-64.
8. Albarracin, F.; Fonseca, R. Plasma cell leukemia. Blood Rev. 2011, 25, 107-112.
9. Kyle, R. A.; Rajkumar, S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23, 3-9.
10. Chng, W. J.; Glebov, O.; Bergsagel, P. L.; Kuehl, W. M. Genetic events in the pathogenesis of multiple myeloma. Best. Pract. Res. Clin. Haematol. 2007, 20, 571-596.
11. Bergsagel, P. L.; Kuehl, W. M.; Zhan, F.; Sawyer, J.; Barlogie, B.; Shaughnessy, J. Jr., Cyclin, D. Dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106, 296-303.
12. Zhan, F.; Huang, Y.; Colla, S.; Stewart, J. P.; Hanamura, I.; Gupta, S.; Epstein, J.; Yaccoby, S.; Sawyer, J.; Burington, B.; Anaissie, E.; Hollmig, K.; Pineda-Roman, M.; Tricot, G.; van, R. F.; Walker, R.; Zangari, M.; Crowley, J.; Barlogie, B.; Shaughnessy, J. D. Jr. The molecular classification of multiple myeloma. Blood 2006, 108, 2020-2028.
13. Agnelli, L.; Bicciato, S.; Mattioli, M.; Fabris, S.; Intini, D.; Verdelli, D.; Baldini, L.; Morabito, F.; Callea, V.; Lombardi, L.; Neri, A. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J. Clin. Oncol. 2005, 23, 7296-7306.
14. Hideshima, T.; Bergsagel, P. L.; Kuehl, W. M.; Anderson, K. C. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104, 607-618.
15. Raab, M. S.; Podar, K.; Breitkreutz, I.; Richardson, P. G.; Anderson, K. C. Multiple myeloma. Lancet 2009, 374, 324-339.
16. Mitsiades, C. S.; Mitsiades, N. S.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Multiple myeloma: a prototypic disease modelfor the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J. Cell Biochem. 2007, 101, 950-968.
17. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341, 1565-1571.
18. Rajkumar, S. V.; Hayman, S. R.; Lacy, M. Q.; Dispenzieri, A.; Geyer, S. M.; Kabat, B.; Zeldenrust, S. R.; Kumar, S.; Greipp, P. R.; Fonseca, R.; Lust, J. A.; Russell, S. J.; Kyle, R. A.; Witzig, T. E.; Gertz, M. A. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106, 4050-4053.
19. Richardson, P. G.; Blood, E.; Mitsiades, C. S.; Jagannath, S.; Zeldenrust, S. R.; Alsina, M.; Schlossman, R. L.; Rajkumar, S. V.; Desikan, K. R.; Hideshima, T.; Munshi, N. C.; Kelly-Colson, K.; Doss, D.; McKenney, M. L.; Gorelik, S.; Warren, D.; Freeman, A.; Rich, R.; Wu, A.; Olesnyckyj, M.; Wride, K.; Dalton, W. S.; Zeldis, J.; Knight, R.; Weller, E.; Anderson, K. C. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108, 3458-3464.
20. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
21. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J. F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352, 2487-2498.
22. Rajkumar, S. V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2011, 86, 57-65.
23. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350-355.
24. Baskerville, S.; Bartel, D. P. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005, 11, 241-247.
25. Kim, Y. K.; Kim, V. N. Processing of intronic microRNAs. EMBO J. 2007, 26, 775-783.
26. Tsuchiya, S.; Okuno, Y.; Tsujimoto, G. MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J. Pharmacol. Sci. 2006, 101, 267-270.
27. Sethupathy, P.; Corda, B.; Hatzigeorgiou, A. G. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 2006, 12, 192-197.
28. Thomas, M.; Lieberman, J.; Lal, A. Desperately seeking microRNA targets. Nat. Struct. Mol. Biol. 2010, 17, 1169-1174.
29. Schickel, R.; Boyerinas, B.; Park, S. M.; Peter, M. E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27, 5959-5974.
30. Calin, G. A.; Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
31. Esquela-Kerscher, A.; Slack, F. J. Oncomirs -microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
32. Calin, G. A.; Dumitru, C. D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C. M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524-15529.
33. Cimmino, A.; Calin, G. A.; Fabbri, M.; Iorio, M. V.; Ferracin, M.; Shimizu, M.; Wojcik, S. E.; Aqeilan, R. I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C. G.; Kipps, T. J.; Negrini, M.; Croce, C. M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102, 13944-13949.
34. Deng, S.; Calin, G. A.; Croce, C. M.; Coukos, G.; Zhang, L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7, 2643-2646.
35. Ventura, A.; Jacks, T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136, 586-591.
36. He, L.; Thomson, J. M.; Hemann, M. T.; Hernando-Monge, E.; Mu, D.; Goodson, S.; Powers, S.; Cordon-Cardo, C.; Lowe, S. W.; Hannon, G. J.; Hammond, S. M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435, 828-833.
37. Eis, P. S.; Tam, W.; Sun, L.; Chadburn, A.; Li, Z.; Gomez, M.F.; Lund, E.; Dahlberg, J. E. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 2005, 102, 3627-3632.
38. Chan, J. A.; Krichevsky, A. M.; Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029-6033.
39. Johnson, C. D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J.; Chin, L.; Brown, D.; Slack, F. J. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67, 7713-7722.
40. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y.; Mitsudomi, T.; Takahashi, T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64, 3753-3756.
41. Camps, C.; Buffa, F. M.; Colella, S.; Moore, J.; Sotiriou, C.; Sheldon, H.; Harris, A. L.; Gleadle, J. M.; Ragoussis, J. Hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 2008, 14, 1340-1348.
42. Garzon, R.; Volinia, S.; Liu, C.G.; Fernandez-Cymering, C.; Palumbo, T.; Pichiorri, F.; Fabbri, M.; Coombes, K.; Alder, H.; Nakamura, T.; Flomenberg, N.; Marcucci, G.; Calin, G. A.; Kornblau, S. M.; Kantarjian, H.; Bloomfield, C. D.; Andreeff, M.; Croce, C. M. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111, 3183-3189.
43. Lotterman, C. D.; Kent, O. A.; Mendell, J. T. Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle 2008, 7, 2493-2499.
44. Lu, J.; Getz, G.; Miska, E. A.; varez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B. L.; Mak, R. H.; Ferrando, A. A.; Downing, J. R.; Jacks, T.; Horvitz, H. R.; Golub, T. R. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
45. Marcucci, G.; Radmacher, M. D.; Maharry, K.; Mrozek, K.; Ruppert, A. S.; Paschka, P.; Vukosavljevic, T.; Whitman, S. P.; Baldus, C. D.; Langer, C.; Liu, C. G.; Carroll, A. J.; Powell, B. L.; Garzon, R.; Croce, C. M.; Kolitz, J. E.; Caligiuri, M. A.; Larson, R. A.; Bloomfield, C. D. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358, 1919-1928.
46. Schetter, A. J.; Leung, S. Y.; Sohn, J. J.; Zanetti, K. A.; Bowman, E. D.; Yanaihara, N.; Yuen, S. T.; Chan, T. L.; Kwong, D. L.; Au, G. K.; Liu, C. G.; Calin, G. A.; Croce, C. M.; Harris, C. C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299, 425-436.
47. Yu, S. L.; Chen, H. Y.; Chang, G. C.; Chen, C. Y.; Chen, H. W.; Singh, S.; Cheng, C. L.; Yu, C. J.; Lee, Y. C.; Chen, H. S.; Su, T. J.; Chiang, C. C.; Li, H. N.; Hong, Q. S.; Su, H. Y.; Chen, C. C.; Chen, W. J.; Liu, C. C.; Chan, W. K.; Chen, W. J.; Li, K. C.; Chen, J. J.; Yang, P. C. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13, 48-57.
48. O'Carroll, D.; Mecklenbrauker, I.; Das, P. P.; Santana, A.; Koenig, U.; Enright, A. J.; Miska, E. A.; Tarakhovsky, A. A Slicerindependent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev. 2007, 21, 1999-2004.
49. Koralov, S. B.; Muljo, S. A.; Galler, G. R.; Krek, A.; Chakraborty, T.; Kanellopoulou, C.; Jensen, K.; Cobb, B. S.; Merkenschlager, M.; Rajewsky, N.; Rajewsky, K. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008, 132, 860-874.
50. Lawrie, C. H.; Cooper, C. D.; Ballabio, E.; Chi, J.; Tramonti, D.; Hatton, C. S. Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy. Br. J. Haematol. 2009, 145, 545-548.
51. Xiao, C.; Calado, D. P.; Galler, G.; Thai, T. H.; Patterson, H. C.; Wang, J.; Rajewsky, N.; Bender, T. P.; Rajewsky, K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131, 146-159.
52. Zhou, B.; Wang, S.; Mayr, C.; Bartel, D. P.; Lodish, H. F. MiR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc. Natl. Acad. Sci. USA 2007, 104, 7080-7085.
53. Fulci, V.; Chiaretti, S.; Goldoni, M.; Azzalin, G.; Carucci, N.; Tavolaro, S.; Castellano, L.; Magrelli, A.; Citarella, F.; Messina, M.; Maggio, R.; Peragine, N.; Santangelo, S.; Mauro, F. R.; Landgraf, P.; Tuschl, T.; Weir, D. B.; Chien, M.; Russo, J. J.; Ju, J.; Sheridan, R.; Sander, C.; Zavolan, M.; Guarini, A.; Foa, R.; Macino, G. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109, 4944-4951.
54. Roehle, A.; Hoefig, K. P.; Repsilber, D.; Thorns, C.; Ziepert, M.; Wesche, K. O.; Thiere, M.; Loeffler, M.; Klapper, W.; Pfreundschuh, M.; Matolcsy, A.; Bernd, H. W.; Reiniger, L.; Merz, H.; Feller, A. C. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br. J. Haematol. 2008, 142, 732-744.
55. Zanette, D. L.; Rivadavia, F.; Molfetta, G. A.; Barbuzano, F. G.; Proto-Siqueira, R.; Silva-Jr, W. A.; Falcao, R. P.; Zago, M.A. MiRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 2007, 40, 1435-1440.
56. Zhao, J. J.; Lin, J.; Lwin, T.; Yang, H.; Guo, J.; Kong, W.; Dessureault, S.; Moscinski, L. C.; Rezania, D.; Dalton, W. S.; Sotomayor, E.; Tao, J.; Cheng, J.Q. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115, 2630-2639.
57. Ventura, A.; Young, A. G.; Winslow, M. M.; Lintault, L.; Meissner, A.; Erkeland, S. J.; Newman, J.; Bronson, R. T.; Crowley, D.; Stone, J. R.; Jaenisch, R.; Sharp, P. A.; Jacks, T. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132, 875-886.
58. Xiao, C.; Srinivasan, L.; Calado, D. P.; Patterson, H. C.; Zhang, B.; Wang, J.; Henderson, J. M.; Kutok, J. L.; Rajewsky, K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008, 9, 405-414.
59. O'Donnell, K. A.; Wentzel, E. A.; Zeller, K. I.; Dang, C. V.; Mendell, J.T. C-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435, 839-843.
60. Olive, V.; Jiang, I.; He, L. Mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol. 2010, 42, 1348-1354.
61. Rodriguez, A.; Vigorito, E.; Clare, S.; Warren, M. V.; Couttet, P.; Soond, D. R.; van Dongen, S.; Grocock, R. J.; Das, P. P.; Miska, E. A.; Vetrie, D.; Okkenhaug, K.; Enright, A. J.; Dougan, G.; Turner, M.; Bradley, A. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316, 608-611.
62. Tili, E.; Croce, C. M.; Michaille, J.J. MiR-155: on the crosstalkbetween inflammation and cancer. Int. Rev. Immunol. 2009, 28, 264-284.
63. Vigorito, E.; Perks, K. L.; Abreu-Goodger, C.; Bunting, S.; Xiang, Z.; Kohlhaas, S.; Das, P. P.; Miska, E. A.; Rodriguez, A.; Bradley, A.; Smith, K. G.; Rada, C.; Enright, A. J.; Toellner, K. M.; Maclennan, I. C.; Turner, M. MicroRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007, 27, 847-859.
64. Faraoni, I.; Antonetti, F. R.; Cardone, J.; Bonmassar, E. MiR-155 gene: A typical multifunctional microRNA. Biochim. Biophys. Acta 2009, 1792, 497-505.
65. Costinean, S.; Zanesi, N.; Pekarsky, Y.; Tili, E.; Volinia, S.; Heerema, N.; Croce, C. M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 7024-7029.
66. Dorsett, Y.; McBride, K. M.; Jankovic, M.; Gazumyan, A.; Thai, T. H.; Robbiani, D. F.; Di, V. M.; San-Martin, B. R.; Heidkamp, G.; Schwickert, T. A.; Eisenreich, T.; Rajewsky, K.; Nussenzweig, M. C. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008, 28, 630-638.
67. Teng, G.; Hakimpour, P.; Landgraf, P.; Rice, A.; Tuschl, T.; Casellas, R.; Papavasiliou, F.N. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 2008, 28, 621-629.
68. Kluiver, J.; Poppema, S.; de, J. D.; Blokzijl, T.; Harms, G.; Jacobs, S.; Kroesen, B. J.; van den, B. A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 2005, 207, 243-249.
69. Metzler, M.; Wilda, M.; Busch, K.; Viehmann, S.; Borkhardt, A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes. Cancer 2004, 39, 167-169.
70. Rai, D.; Kim, S. W.; McKeller, M. R.; Dahia, P. L.; Aguiar, R.C. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc. Natl. Acad. Sci. USA 2010, 107, 3111-3116.
71. Calin, G. A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wojcik, S. E.; Iorio, M. V.; Visone, R.; Sever, N. I.; Fabbri, M.; Iuliano, R.; Palumbo, T.; Pichiorri, F.; Roldo, C.; Garzon, R.; Sevignani, C.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C. G.; ipps, T. J.; Negrini, M.; Croce, C. M. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353, 1793-1801.
72. Basso, K.; Sumazin, P.; Morozov, P.; Schneider, C.; Maute, R. L.; Kitagawa, Y.; Mandelbaum, J.; Haddad, J. Jr.; Chen, C. Z.; Califano, A.; la-Favera, R. Identification of the human mature B cell miRNome. Immunity 2009, 30, 744-752.
73. Jima, D. D.; Zhang, J.; Jacobs, C.; Richards, K. L.; Dunphy, C. H.; Choi, W. W.; Yan, A. W.; Srivastava, G.; Czader, M. B.; Rizzieri, D. A.; Lagoo, A. S.; Lugar, P. L.; Mann, K. P.; Flowers, C. R.; Bernal-Mizrachi, L.; Naresh, K. N.; Evens, A. M.; Gordon, L. I.; Luftig, M.; Friedman, D. R.; Weinberg, J. B.; Thompson, M. A.; Gill, J. I.; Liu, Q.; How, T.; Grubor, V.; Gao, Y.; Patel, A.; Wu, H.; Zhu, J.; Blobe, G. C.; Lipsky, P. E.; Chadburn, A.; Dave, S. S. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010, 116, e118-e127.
74. Malumbres, R.; Sarosiek, K. A.; Cubedo, E.; Ruiz, J. W.; Jiang, X.; Gascoyne, R. D.; Tibshirani, R.; Lossos, I. S. Differentiation stagespecific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009, 113, 3754-3764.
75. Tan, L. P.; Wang, M.; Robertus, J. L.; Schakel, R. N.; Gibcus, J. H.; Diepstra, A.; Harms, G.; Peh, S. C.; Reijmers, R. M.; Pals, S. T.; Kroesen, B. J.; Kluin, P. M.; Poppema, S.; van den, B. A. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest. 2009, 89, 708-716.
76. Zhang, J.; Jima, D. D.; Jacobs, C.; Fischer, R.; Gottwein, E.; Huang, G.; Lugar, P. L.; Lagoo, A. S.; Rizzieri, D. A.; Friedman, D. R.; Weinberg, J. B.; Lipsky, P. E.; Dave, S. S. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113, 4586-4594.
77. Gururajan, M.; Haga, C. L.; Das, S.; Leu, C. M.; Hodson, D.; Josson, S.; Turner, M.; Cooper, M. D. MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int. Immunol. 2010, 22, 583-592.
78. Navarro, F.; Lieberman, J. Small RNAs guide hematopoietic cell differentiation and function. J. Immunol. 2010, 184, 5939-5947.
79. Ronchetti, D.; Lionetti, M.; Mosca, L.; Agnelli, L.; Andronache, A.; Fabris, S.; Deliliers, G. L.; Neri, A. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC. Med. Genomics 2008, 1, 37.
80. Pichiorri, F.; Suh, S. S.; Ladetto, M.; Kuehl, M.; Palumbo, T.; Drandi, D.; Taccioli, C.; Zanesi, N.; Alder, H.; Hagan, J. P.; Munker, R.; Volinia, S.; Boccadoro, M.; Garzon, R.; Palumbo, A.; Aqeilan, R. I.; Croce, C. M. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA 2008, 105, 12885-12890.
81. Loffler, D.; Brocke-Heidrich, K.; Pfeifer, G.; Stocsits, C.; Hackermuller, J.; Kretzschmar, A. K.; Burger, R.; Gramatzki, M.; Blumert, C.; Bauer, K.; Cvijic, H.; Ullmann, A. K.; Stadler, P. F.; Horn, F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110, 1330-1333.
82. Xiong, Q.; Zhong, Q.; Zhang, J.; Yang, M.; Li, C.; Zheng, P.; Bi, L. J.; Ge, F. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J. Proteome Res. 2012, 11, 2078-2090.
83. Wang, X.; Li, C.; Ju, S.; Wang, Y.; Wang, H.; Zhong, R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk. Lymphoma 2011, 52, 1991-1998.
84. Chen, L.; Li, C.; Zhang, R.; Gao, X.; Qu, X.; Zhao, M.; Qiao, C.; Xu, J.; Li, J. MiR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 2011, 309, 62-70.
85. Shi, M.; Liu, D.; Shen, B.; Guo, N. Helpers of the cellular gatekeeper-miRNAs dance in P53 network. Biochim. Biophys. Acta 2010, 1805, 218-225.
86. Kumar, M.; Lu, Z.; Takwi, A. A.; Chen, W.; Callander, N. S.; Ramos, K. S.; Young, K. H.; Li, Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011, 30, 843-853.
87. Pichiorri, F.; Suh, S. S.; Rocci, A.; De Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D. M. Jr.; Hofmainster, C.; Alder, H.; Garofalo, M.; Di Leva, G.; Volinia, S.; Lin, H. J.; Perrotti, D.; Kuehl, M.; Aqeilan, R. I.; Palumbo, A.; Croce, C. M. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. Cancer Cell 2010, 18, 367-381.
88. Chesi, M.; Bergsagel, P. L. Epigenetics and MicroRNAs Combine to Modulate the MDM2/p53 Axis in Myeloma. Cancer Cell 2010, 18, 299-300.
89. Roccaro, A. M.; Sacco, A.; Thompson, B.; Leleu, X.; Azab, A. K.; Azab, F.; Runnels, J.; Jia, X.; Ngo, H. T.; Melhem, M. R.; Lin, C. P.; Ribatti, D.; Rollins, B. J.; Witzig, T. E.; Anderson, K. C.; Ghobrial, I. M. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113, 6669-6680.
90. Hao, M.; Zhang, L.; An, G.; Meng, H.; Han, Y.; Xie, Z.; Xu, Y.; Li, C.; Yu, Z.; Chang, H.; Qiu, L. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk. Lymphoma 2011, 52, 1787-1794.
91. Hao, M.; Zhang, L.; An, G.; Sui, W.; Yu, Z.; Zou, D.; Xu, Y.; Chang, H.; Qiu, L. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J. Hematol. Oncol. 2011, 4, 37.
92. Lionetti, M.; Agnelli, L.; Mosca, L.; Fabris, S.; Andronache, A.; Todoerti, K.; Ronchetti, D.; Lambertenghi Deliliers, G.; Neri, A. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009, 48, 521-531.
93. Lionetti, M.; Biasiolo, M.; Agnelli, L.; Todoerti, K.; Mosca, L.; Fabris, S.; Sales, G.; Lambertenghi Deliliers, G.; Bicciato, S.; Lombardi, L.; Bortoluzzi, S.; Neri, A. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114, e20-e26.
94. Corthals, S. L.; Jongen-Lavrencic, M.; de Knegt, Y.; Peeters, J. K.; Beverloo, H. B.; Lokhorst, H. M.; Sonneveld, P. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk. Res. 2010, 34, 677-681.
95. Gutierrez, N. C.; Sarasquete, M. E.; Misiewicz-Krzeminska, I.; Delgado, M.; de Las, R. J.; Ticona, F. V.; Ferminan, E.; Martin-Jimenez, P.; Chillon, C.; Risueno, A.; Hernandez, J. M.; Garcia-Sanz, R.; Gonzalez, M.; San Miguel, J. F. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24, 629-637.
96. Chi, J.; Ballabio, E.; Chen, X. H.; Kusec, R.; Taylor, S.; Hay, D.; Tramonti, D.; Saunders, N. J.; Littlewood, T.; Pezzella, F.; Boultwood, J.; Wainscoat, J. S.; Hatton, C. S.; Lawrie, C. H. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol. Direct. 2011, 6, 23.
97. Carrasco, D. R.; Tonon, G.; Huang, Y.; Zhang, Y.; Sinha, R.; Feng, B.; Stewart, J. P.; Zhan, F.; Khatry, D.; Protopopova, M.; Protopopov, A.; Sukhdeo, K.; Hanamura, I.; Stephens, O.; Barlogie, B.; Anderson, K. C.; Chin, L.; Shaughnessy, J. D., Jr.; Brennan, C.; Depinho, R. A. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9, 313-325.
98. Mattioli, M.; Agnelli, L.; Fabris, S.; Baldini, L.; Morabito, F.; Bicciato, S.; Verdelli, D.; Intini, D.; Nobili, L.; Cro, L.; Pruneri, G.; Callea, V.; Stelitano, C.; Maiolo, A.T.; Lombardi, L.; Neri, A. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005, 24, 2461-2473.
99. Bergsagel, P. L.; Kuehl, W. M. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 2005, 23, 6333-6338.
100. Agnelli, L.; Bicciato, S.; Fabris, S.; Baldini, L.; Morabito, F.; Intini, D.; Verdelli, D.; Callegaro, A.; Bertoni, F.; Lambertenghi-Deliliers, G.; Lombardi, L.; Neri, A. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 2007, 92, 56-65.
101. Shaughnessy, J. D. Jr.; Zhan, F.; Burington, B. E.; Huang, Y.; Colla, S.; Hanamura, I.; Stewart, J. P.; Kordsmeier, B.; Randolph, C.; Williams, D. R.; Xiao, Y.; Xu, H.; Epstein, J.; Anaissie, E.; Krishna, S. G.; Cottler-Fox, M.; Hollmig, K.; Mohiuddin, A.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Sawyer, J.; Alsayed, Y.; Walker, R.; Zangari, M.; Crowley, J.; Barlogie, B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109, 2276-2284.
102. Fabris, S.; Ronchetti, D.; Agnelli, L.; Baldini, L.; Morabito, F.; Bicciato, S.; Basso, D.; Todoerti, K.; Lombardi, L.; Lambertenghi-Deliliers, G.; Neri, A. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia 2007, 21, 1113-1116.
103. Agnelli, L.; Fabris, S.; Bicciato, S.; Basso, D.; Baldini, L.; Morabito, F.; Verdelli, D.; Todoerti, K.; Lambertenghi-Deliliers, G.; Lombardi, L.; Neri, A. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br. J. Haematol. 2007, 136, 565-573.
104. Chng, W. J.; Kumar, S.; Vanwier, S.; Ahmann, G.; Price-Troska, T.; Henderson, K.; Chung, T. H.; Kim, S.; Mulligan, G.; Bryant, B.; Carpten, J.; Gertz, M.; Rajkumar, S. V.; Lacy, M.; Dispenzieri, A.; Kyle, R.; Greipp, P.; Bergsagel, P. L.; Fonseca, R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007, 67, 2982-2989.
105. Calin, G. A.; Sevignani, C.; Dumitru, C. D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C. M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004.
106. Calin, G. A.; Croce, C. M. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006, 25, 6202-6210.
107. Zhang, L.; Huang, J.; Yang, N.; Greshock, J.; Megraw, M. S.; Giannakakis, A.; Liang, S.; Naylor, T. L.; Barchetti, A.; Ward, M. R.; Yao, G.; Medina, A.; O'brien-Jenkins, A.; Katsaros, D.; Hatzigeorgiou, A.; Gimotty, P. A.; Weber, B. L.; Coukos, G. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 9136-9141.
108. Zhang, L.; Volinia, S.; Bonome, T.; Calin, G. A.; Greshock, J.; Yang, N.; Liu, C. G.; Giannakakis, A.; Alexiou, P.; Hasegawa, K.; Johnstone, C. N.; Megraw, M. S.; Adams, S.; Lassus, H.; Huang, J.; Kaur, S.; Liang, S.; Sethupathy, P.; Leminen, A.; Simossis, V. A.; Sandaltzopoulos, R.; Naomoto, Y.; Katsaros, D.; Gimotty, P. A.; DeMichele, A.; Huang, Q.; Butzow, R.; Rustgi, A. K.; Weber, B. L.; Birrer, M. J.; Hatzigeorgiou, A. G.; Croce, C. M.; Coukos, G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 2008, 105, 7004-7009.
109. Jenner, M. W.; Leone, P. E.; Walker, B. A.; Ross, F. M.; Johnson, D. C.; Gonzalez, D.; Chiecchio, L.; Dachs, C. E.; Dagrada, G. P.; Nightingale, M.; Protheroe, R. K.; Stockley, D.; Else, M.; Dickens, N. J.; Cross, N. C.; Davies, F. E.; Morgan, G. J. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007, 110, 3291-3300.
110. Guo, S.; Lu, J.; Schlanger, R.; Zhang, H.; Wang, J. Y.; Fox, M. C.; Purton, L. E.; Fleming, H. H.; Cobb, B.; Merkenschlager, M.; Golub, T. R.; Scadden, D. T. MicroRNA miR-125a controls hematopoietic stem cell number. Proc. Natl. Acad. Sci. USA 2010, 107, 14229-14234.
111. Fracchiolla, N. S.; Colombo, G.; Finelli, P.; Maiolo, A. T.; Neri, A. EHT, a new member of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute myeloid leukemias. Blood 1998, 92, 3481-3484.
112. Lindberg, S. R.; Olsson, A.; Persson, A. M.; Olsson, I. The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation. Exp. Hematol. 2005, 33, 189-198.
113. Chiusaroli, R.; Knobler, H.; Luxenburg, C.; Sanjay, A.; Granot-Attas, S.; Tiran, Z.; Miyazaki, T.; Harmelin, A.; Baron, R.; Elson, A. Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo. Mol. Biol. Cell 2004, 15, 234-244.
114. Tanuma, N.; Shima, H.; Nakamura, K.; Kikuchi, K. Protein tyrosine phosphatase epsilon C selectively inhibits interleukin-6-and interleukin-10-induced JAK-STAT signaling. Blood 2001, 98, 3030-3034.
115. Corthals, S. L.; Sun, S. M.; Kuiper, R.; de, K. Y.; Broyl, A.; van der, H. B.; Beverloo, H. B.; Peeters, J. K.; El, J. L.; Lokhorst, H. M.; Zweegman, S.; Jongen-Lavrencic, M.; Sonneveld, P. MicroRNA signatures characterize multiple myeloma patients. Leukemia 2011, 25, 1784-1789.
116. Zhou, Y.; Chen, L.; Barlogie, B.; Stephens, O.; Wu, X.; Williams, D. R.; Cartron, M. A.; van Rhee, F.; Nair, B.; Waheed, S.; Pineda-Roman, M.; Alsayed, Y.; Anaissie, E.; Shaughnessy, J.D. Jr. Highrisk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc. Natl. Acad. Sci. USA 2010, 107, 7904-7909.
117. Chiosea, S.; Jelezcova, E.; Chandran, U.; Luo, J.; Mantha, G.; Sobol, R. W.; Dacic, S. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007, 67, 2345-2350.
118. Kumar, M. S.; Lu, J.; Mercer, K. L.; Golub, T. R.; Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39, 673-677.
119. Lin, R. J.; Lin, Y. C.; Chen, J.; Kuo, H. H.; Chen, Y. Y.; Diccianni, M. B.; London, W. B.; Chang, C. H.; Yu, A.L. MicroRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010, 70, 7841-7850.
120. Merritt, W. M.; Lin, Y. G.; Han, L. Y.; Kamat, A. A.; Spannuth, W. A.; Schmandt, R.; Urbauer, D.; Pennacchio, L. A.; Cheng, J. F.; Nick, A. M.; Deavers, M. T.; Mourad-Zeidan, A.; Wang, H.; Mueller, P.; Lenburg, M. E.; Gray, J. W.; Mok, S.; Birrer, M. J.; Lopez-Berestein, G.; Coleman, R. L.; Bar-Eli, M.; Sood, A. K. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 2008, 359, 2641-2650.
121. Sarasquete, M. E.; Gutierrez, N. C.; Misiewicz-Krzeminska, I.; Paiva, B.; Chillon, M. C.; Alcoceba, M.; Garcia-Sanz, R.; Hernandez-Rivas, J. M.; Gonzalez, M.; San Miguel, J. F. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2011, 96, 468-471.
122. Kumar, M. S.; Pester, R. E.; Chen, C. Y.; Lane, K.; Chin, C.; Lu, J.; Kirsch, D. G.; Golub, T. R.; Jacks, T. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009, 23, 2700-2704.
123. Fernandez de Larrea, C.; Navarro, A.; Tejero, R.; Tovar, N.; Diaz, T.; Cibeira, M. T.; Rosinol, L.; Rovira, M.; Ferrer, G.; Rozman, M.; Monzo, M.; Blade, J. Impact of mirsnps on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin. Cancer Res. 2012, 18, 3697-3704.
124. Iorio, M. V.; Piovan, C.; Croce, C. M. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim. Biophys. Acta 2010, 1799, 694-701.
125. Chim, C. S.; Wong, K. Y.; Qi, Y.; Loong, F.; Lam, W. L.; Wong, L. G.; Jin, D. Y.; Costello, J. F.; Liang, R. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31, 745-750.
126. Wong, K. Y.; So, C. C.; Loong, F.; Chung, L. P.; Lam, W. W.; Liang, R.; Li, G. K.; Jin, D. Y.; Chim, C. S. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011, 6, e19027.
127. Wong, K. Y.; Yim, R. L.; So, C. C.; Jin, D. Y.; Liang, R.; Chim, C. S. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011, 118, 5901-5904.
128. Wong, K. Y.; Liang, R.; So, C. C.; Jin, D. Y.; Costello, J. F.; Chim, C. S. Epigenetic silencing of MIR203 in multiple myeloma. Br. J. Haematol. 2011, 154, 569-578.
129. Esquela-Kerscher, A.; Trang, P.; Wiggins, J. F.; Patrawala, L.; Cheng, A.; Ford, L.; Weidhaas, J. B.; Brown, D.; Bader, A. G.; Slack, F. J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7, 759-764.
130. Kumar, M. S.; Erkeland, S. J.; Pester, R. E.; Chen, C. Y.; Ebert, M. S.; Sharp, P. A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 2008, 105, 3903-3908.
131. Trang, P.; Medina, P. P.; Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A. G.; Weidhaas, J. B.; Slack, F. J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29, 1580-1587.
132. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
133. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D'Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; Bartucci, M.; Muto, G.; Peschle, C.; De, M. R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14, 1271-1277.
134. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R. U.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A. G.; Brown, D.; Ochiya, T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18, 181-187.
135. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
136. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H. F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E. M.; Kauppinen, S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452, 896-899.
137. Gentner, B.; Schira, G.; Giustacchini, A.; Amendola, M.; Brown, B. D.; Ponzoni, M.; Naldini, L. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 2009, 6, 63-66.